 Familiar to this autonomia is a rare disease that affects what's called the autonomic nervous system and that has to do with involuntary functions, particularly control of blood pressure, digestion, tearing, sweating, etc. So it's a severe disease that affects quality of life and overall lifespan and it happens to be due to a mutation that's almost exclusively found in the Ashkenazi Jewish population and that mutation affects a process called messenger RNA splicing which is relevant to virtually all the genes but this particular gene doesn't function well because of that mutation that affects splicing and so that's a process that we have been working on for many years and we use a strategy to correct effective splicing. We previously used this strategy to develop a drug called Spenraza for spinal muscular atrophy, a different neurological disorder that proved to be very effective and it corrects an error in splicing for a gene that's defective in that particular disease and we now apply the same strategy to restore correct splicing of the IKB cap gene in the context of this disease familial dysautonomia. So our hope is that molecule that we described in this recent publication will eventually develop into a therapy for familial dysautonomia as at present time there isn't any approved therapy for this disease.